Articles related to CLINICAL TRIALS

In this study, dostarlimab combined with carboplatin-paclitaxel demonstrated a marked improvement in progression-free and overall survival among endometrial cancer patients, particularly those with genetic markers for dMMR and MSI-H.

Reevaluating beta-blocker therapy post-myocardial infarction, a recent trial found no significant difference in the composite primary endpoint of death from any cause or new myocardial infarction between patients treated with long-term beta-blockers and those without.

In a recent phase 3 trial, alectinib has shown a notable improvement in both disease-free and CNS disease-free survival in patients with ALK-positive NSCLC, indicating a robust alternative to platinum-based chemotherapy regimens.

This study sheds light on lixisenatide’s potential in Parkinson’s disease, showing a notable slowing of motor disability progression, although accompanied by gastrointestinal side effects, underlining the importance of further research to validate these findings.

This study introduces a pivotal model that aids physicians in making informed decisions regarding bone marrow sampling for MGUS patients, utilizing a comprehensive set of biomarkers to predict the progression to SMM or worse conditions with high accuracy.

Explore this development in metastatic melanoma treatment with the FDA’s accelerated approval of TIL therapy, a promising approach for patients who have exhausted other options.